Shares of SCYNEXIS, Inc. (NASDAQ:SCYX) have been assigned a consensus rating of “Buy” from the eight ratings firms that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have given a buy recommendation to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $8.40.

A number of equities research analysts have weighed in on the stock. Zacks Investment Research raised shares of SCYNEXIS from a “hold” rating to a “buy” rating and set a $2.75 target price on the stock in a report on Tuesday, October 10th. Guggenheim began coverage on shares of SCYNEXIS in a research note on Tuesday, October 24th. They issued a “buy” rating and a $6.00 price objective on the stock. HC Wainwright set a $14.00 price objective on shares of SCYNEXIS and gave the company a “buy” rating in a research note on Wednesday, August 16th. Finally, ValuEngine lowered shares of SCYNEXIS from a “sell” rating to a “strong sell” rating in a research note on Tuesday, August 22nd.

Institutional investors have recently added to or reduced their stakes in the stock. National Asset Management Inc. acquired a new position in shares of SCYNEXIS during the 2nd quarter valued at $551,000. Federated Investors Inc. PA raised its holdings in SCYNEXIS by 23.5% during the second quarter. Federated Investors Inc. PA now owns 4,208,400 shares of the company’s stock worth $7,533,000 after buying an additional 800,040 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in SCYNEXIS by 1.4% during the first quarter. Bank of New York Mellon Corp now owns 37,523 shares of the company’s stock worth $103,000 after buying an additional 512 shares during the last quarter. DAFNA Capital Management LLC raised its holdings in SCYNEXIS by 32.7% during the second quarter. DAFNA Capital Management LLC now owns 506,900 shares of the company’s stock worth $907,000 after buying an additional 125,000 shares during the last quarter. Finally, GSA Capital Partners LLP raised its holdings in SCYNEXIS by 33.7% during the second quarter. GSA Capital Partners LLP now owns 176,700 shares of the company’s stock worth $316,000 after buying an additional 44,500 shares during the last quarter. Institutional investors own 30.45% of the company’s stock.

SCYNEXIS (NASDAQ SCYX) traded up $0.06 on Monday, reaching $1.94. 133,110 shares of the company’s stock were exchanged, compared to its average volume of 340,665. SCYNEXIS has a 52-week low of $1.52 and a 52-week high of $4.04. The company has a debt-to-equity ratio of 0.43, a quick ratio of 7.30 and a current ratio of 7.30.

TRADEMARK VIOLATION WARNING: “SCYNEXIS, Inc. (SCYX) Receives Average Rating of “Buy” from Analysts” was reported by Daily Political and is the property of of Daily Political. If you are accessing this story on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this story can be read at https://www.dailypolitical.com/2017/11/20/scynexis-inc-scyx-receives-average-rating-of-buy-from-analysts.html.

About SCYNEXIS

SCYNEXIS, Inc is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains.

Analyst Recommendations for SCYNEXIS (NASDAQ:SCYX)

Receive News & Ratings for SCYNEXIS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS Inc. and related companies with MarketBeat.com's FREE daily email newsletter.